Recurrence patterns and adjuvant therapy strategies in patients with esophageal squamous cell carcinoma who achieved pathological complete response after neoadjuvant immunochemotherapy: A high-volume retrospective study
- 19 December 2025
- journal article
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 52 (2) , 111360
Abstract
No abstract availableKeywords
Funding Information
- Natural Science Foundation of Shaanxi Province (2024JC-YBMS-738)
- Natural Science Foundation of Shaanxi Province (2024JC-YBMS-773)
- Sanming Project of Medicine in Shenzen Municipality (SZSM201612097)
- Xi'an Jiaotong University (xzy012023125)
This publication has 22 references indexed in Scilit:
- Neoadjuvant chemotherapy with or without camrelizumab in resectable esophageal squamous cell carcinoma: the randomized phase 3 ESCORT-NEO/NCCES01 trialNature Medicine, 2024
- Predictive role of ctDNA in esophageal squamous cell carcinoma receiving definitive chemoradiotherapy combined with toripalimabNature Communications, 2024
- Immunotherapy for Resectable Locally Advanced Esophageal CarcinomaThe Annals of Thoracic Surgery, 2024
- Two-year outcomes of clinical N2-3 esophageal squamous cell carcinoma after neoadjuvant chemotherapy and immunotherapy from the phase 2 NICE studyThe Journal of Thoracic and Cardiovascular Surgery, 2023
- Neoadjuvant adebrelimab in locally advanced resectable esophageal squamous cell carcinoma: a phase 1b trialNature Medicine, 2023
- Efficacy and safety of neoadjuvant immunotherapy in surgically resectable esophageal cancer: A systematic review and meta-analysisInternational Journal of Surgery, 2022
- Tislelizumab combined with chemotherapy as neoadjuvant therapy for surgically resectable esophageal cancer: A prospective, single-arm, phase II study (TD-NICE)International Journal of Surgery, 2022
- Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell CarcinomaJAMA, 2021
- Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 studyThe Lancet, 2021
- Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiationCancer, 2005